Toxicity of high-dose 90Y-ibritumomab tiuxetan, etoposide, and cyclophosphamide followed by ASCT in 31 patients with poor-risk and relapsed B-cell NHL, by grade of severity
Toxicity . | Grade 1, no. (%) . | Grade 2, no. (%) . | Grade 3, no. (%) . | Grade 4, no. (%) . |
|---|---|---|---|---|
| Skin rashes | 5 (16) | 7 (23) | 4 (13) | 0 (0) |
| Nausea/vomiting | 5 (16) | 12 (39) | 9 (29) | 0 (0) |
| Mucositis | 3 (10) | 11 (35) | 11 (35) | 0 (0) |
| Infection | 0 (0) | 1 (3) | 23 (74) | 1 (3) |
| Cardiac | 6 (19) | 0 (0) | 3 (10) | 0 (0) |
| Hypotension | 0 (0) | 10 (32) | 2 (6) | 0 (0) |
| Pulmonary | 2 (6) | 4 (13) | 4 (13) | 0 (0) |
| Hepatic | 19 (61) | 4 (13) | 2 (6) | 1 (3) |
Toxicity . | Grade 1, no. (%) . | Grade 2, no. (%) . | Grade 3, no. (%) . | Grade 4, no. (%) . |
|---|---|---|---|---|
| Skin rashes | 5 (16) | 7 (23) | 4 (13) | 0 (0) |
| Nausea/vomiting | 5 (16) | 12 (39) | 9 (29) | 0 (0) |
| Mucositis | 3 (10) | 11 (35) | 11 (35) | 0 (0) |
| Infection | 0 (0) | 1 (3) | 23 (74) | 1 (3) |
| Cardiac | 6 (19) | 0 (0) | 3 (10) | 0 (0) |
| Hypotension | 0 (0) | 10 (32) | 2 (6) | 0 (0) |
| Pulmonary | 2 (6) | 4 (13) | 4 (13) | 0 (0) |
| Hepatic | 19 (61) | 4 (13) | 2 (6) | 1 (3) |